Russell Investments Group Ltd. Has $2.94 Million Holdings in Charles River Laboratories International, Inc. $CRL

Key Points

• Russell Investments Group Ltd. reduced its stake in Charles River Laboratories International by 35.9% during the first quarter, selling 10,937 shares and now holding 19,508 shares valued at approximately $2.94 million.
• Several institutional investors substantially increased their stakes in Charles River Laboratories, with Assenagon Asset Management raising its stake by 1,721.1% and now owning 570,097 shares worth about $85.81 million.
• Analysts have raised various price targets for Charles River Laboratories, with a consensus target price of $175.69 and a mix of ratings including five "Buy," nine "Hold," and one "Sell."

Russell Investments Group Ltd. reduced its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 35.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 19,508 shares of the medical research company's stock after selling 10,937 shares during the period. Russell Investments Group Ltd.'s holdings in Charles River Laboratories International were worth $2,936,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Invesco Ltd. grew its stake in shares of Charles River Laboratories International by 7.2% in the 1st quarter. Invesco Ltd. now owns 1,108,358 shares of the medical research company's stock valued at $166,830,000 after purchasing an additional 74,178 shares during the period. Ariel Investments LLC grew its stake in shares of Charles River Laboratories International by 18.9% in the 4th quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock valued at $197,029,000 after purchasing an additional 169,640 shares during the period. Mackenzie Financial Corp grew its stake in shares of Charles River Laboratories International by 2.6% in the 1st quarter. Mackenzie Financial Corp now owns 1,002,951 shares of the medical research company's stock valued at $150,964,000 after purchasing an additional 25,878 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Charles River Laboratories International by 25.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 663,504 shares of the medical research company's stock valued at $122,482,000 after purchasing an additional 135,986 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Charles River Laboratories International by 4.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 577,322 shares of the medical research company's stock valued at $86,899,000 after purchasing an additional 24,347 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CRL shares. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Barclays increased their price target on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an "equal weight" rating in a research report on Thursday, August 7th. Evercore ISI increased their price target on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Wall Street Zen lowered Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 17th. Finally, Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and increased their price target for the stock from $150.00 to $200.00 in a research report on Wednesday, July 9th. Five research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $175.69.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares of the company's stock, valued at $3,800,681.60. This represents a 3.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Trading Up 0.0%

CRL traded up $0.07 during mid-day trading on Friday, reaching $163.29. The stock had a trading volume of 860,239 shares, compared to its average volume of 954,372. The stock has a market capitalization of $8.04 billion, a P/E ratio of -122.77, a P/E/G ratio of 5.21 and a beta of 1.48. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.10 and a current ratio of 1.36. The firm's fifty day simple moving average is $159.32 and its two-hundred day simple moving average is $148.78. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. The company had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm's quarterly revenue was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.80 EPS. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).